GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Beneish M-Score

Biotricity (Biotricity) Beneish M-Score : -8.44 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biotricity Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -8.44 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biotricity's Beneish M-Score or its related term are showing as below:

BTCY' s Beneish M-Score Range Over the Past 10 Years
Min: -12.94   Med: -5.77   Max: 18.92
Current: -8.44

During the past 10 years, the highest Beneish M-Score of Biotricity was 18.92. The lowest was -12.94. And the median was -5.77.


Biotricity Beneish M-Score Historical Data

The historical data trend for Biotricity's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Beneish M-Score Chart

Biotricity Annual Data
Trend Aug14 Aug15 Dec16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -8.16 -6.40 -5.34 -4.77

Biotricity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 -4.77 -5.77 -7.24 -8.44

Competitive Comparison of Biotricity's Beneish M-Score

For the Medical Devices subindustry, Biotricity's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotricity's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biotricity's Beneish M-Score falls into.



Biotricity Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biotricity for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5801+0.528 * 0.9023+0.404 * 1.7055+0.892 * 1.2855+0.115 * 0.5902
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6183+4.679 * -1.245899-0.327 * 1.7605
=-8.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $1.80 Mil.
Revenue was 2.973 + 2.891 + 3.021 + 2.742 = $11.63 Mil.
Gross Profit was 2.168 + 1.999 + 1.917 + 1.535 = $7.62 Mil.
Total Current Assets was $3.93 Mil.
Total Assets was $5.49 Mil.
Property, Plant and Equipment(Net PPE) was $1.33 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $14.29 Mil.
Total Current Liabilities was $18.62 Mil.
Long-Term Debt & Capital Lease Obligation was $12.46 Mil.
Net Income was -2.808 + -3.691 + -3.413 + -4.672 = $-14.58 Mil.
Non Operating Income was -0.325 + -0.155 + 0.121 + 0.016 = $-0.34 Mil.
Cash Flow from Operations was -1.306 + -2.39 + -1.832 + -1.878 = $-7.41 Mil.
Total Receivables was $2.41 Mil.
Revenue was 2.459 + 2.381 + 2.056 + 2.149 = $9.05 Mil.
Gross Profit was 1.402 + 1.28 + 1.225 + 1.441 = $5.35 Mil.
Total Current Assets was $4.79 Mil.
Total Assets was $6.65 Mil.
Property, Plant and Equipment(Net PPE) was $1.70 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $17.98 Mil.
Total Current Liabilities was $7.29 Mil.
Long-Term Debt & Capital Lease Obligation was $14.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.798 / 11.627) / (2.411 / 9.045)
=0.15464 / 0.266556
=0.5801

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5.348 / 9.045) / (7.619 / 11.627)
=0.591266 / 0.655285
=0.9023

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.932 + 1.333) / 5.486) / (1 - (4.794 + 1.696) / 6.647)
=0.040284 / 0.02362
=1.7055

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=11.627 / 9.045
=1.2855

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.003 / (0.003 + 1.696)) / (0.004 / (0.004 + 1.333))
=0.001766 / 0.002992
=0.5902

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.289 / 11.627) / (17.978 / 9.045)
=1.22895 / 1.987617
=0.6183

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((12.456 + 18.619) / 5.486) / ((14.096 + 7.291) / 6.647)
=5.664419 / 3.217542
=1.7605

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-14.584 - -0.343 - -7.406) / 5.486
=-1.245899

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biotricity has a M-score of -8.44 suggests that the company is unlikely to be a manipulator.


Biotricity Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Biotricity's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotricity (Biotricity) Business Description

Traded in Other Exchanges
Address
275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.
Executives
Chester P White director 447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon director 1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts director 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq director, 10 percent owner, officer: CEO and Chairman of the Board C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou officer: Chief Financial Officer C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065